Cornerstone Advisors LLC Makes New Investment in Merck & Co., Inc. $MRK

Cornerstone Advisors LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK – Free Report) in the third quarter, Holdings Channel.com reports. The fund acquired 60,548 shares of the company’s stock, valued at approximately $8,798,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. boosted its holdings in Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after acquiring an additional 1,073,507 shares during the period. State Street Corp grew its position in Merck & Co., Inc. by 0.9% in the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after acquiring an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP grew its position in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after acquiring an additional 1,934,312 shares in the last quarter. Fisher Asset Management LLC increased its stake in Merck & Co., Inc. by 8.3% during the third quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company’s stock worth $6,059,345,000 after purchasing an additional 3,183,169 shares during the period. Finally, Bank of America Corp DE increased its stake in Merck & Co., Inc. by 10.5% during the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on MRK shares. Barclays increased their price target on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an “overweight” rating in a research report on Monday, October 26th. Cantor Fitzgerald lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $155.00 and gave the company a “neutral” rating in a report on Monday, November 2nd. Citigroup lifted their price objective on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a report on Monday, October 12th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 7th. Finally, HSBC increased their target price on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $155.74.

Get Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Trading Up 0.5%

NYSE:MRK opened at $147.74 on Friday. The firm has a market cap of $364.21 billion, a PE ratio of 152.31, a price-to-earnings-growth ratio of 6.74 and a beta of 0.13. The stock has a fifty day moving average price of $146.16 and a 200 day moving average price of $128.61. Merck & Co., Inc. has a 12-month low of $91.49 and a 12-month high of $156.92. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The company had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the prior year, the business earned $2.58 EPS. Merck & Co., Inc.’s revenue was up 4.7% on a year-over-year basis. Sell-side analysts anticipate that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.

Trending Headlines about Merck & Co., Inc.

Here are a few of the latest headlines about MRK:

  • Positive Sentiment: The EMA’s CHMP recommended expanding ENFLONSIA’s use to help prevent severe RSV lower respiratory tract disease in vulnerable children up to 24 months old, including through their second RSV season. The broader eligible population could support the medicine’s commercial opportunity in Europe. Merck ENFLONSIA CHMP recommendation
  • Positive Sentiment: The CHMP also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cell carcinoma after anti-PD-1/PD-L1 treatment. This would extend WELIREG into another treatment setting and expand Merck’s oncology portfolio in Europe. Merck WELIREG CHMP recommendation
  • Neutral Sentiment: Both decisions are CHMP recommendations; European Commission approval is still needed. Any financial contribution will also depend on launch timing, uptake and competition.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.